First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Optitrop-Lung05 is a hit, as promised, and then some.
Strategist-Frontline is set to begin, as the company reports first-line velzatinib data at ASCO.
First human data for BeOne’s BGB-B2033 lack the wow factor.
The company diverges from Summit and Bristol/BioNTech with a pivotal endometrial trial.
ABO2109 and ODI-2001 are starting their first human studies.
Parabilis’s zolucatetide bids to be third to a rather small market.
